CTIM-22. PHASE 1 TRIAL OF OSIMERTINIB WITH STEREOTACTIC RADIOSURGERY (SRS) IN PATIENTS WITH BRAIN METASTASES FROM EGFR POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

BACKGROUND: Osimertinib is an oral, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor activating mutation (EGFRm) and the resistance mutation (T790M) that is FDA approved for patients with EGFR mutant lung cancer. The synergism between Osimertinib and rad...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuro Oncol
Huvudupphovsmän: Rauf, Yasmeen, Kotecha, Rupesh, Fadul, Camilo, Evanoff, Wendi, Suh, John, Chao, Samuel, Murphy, Erin, Yu, Jennifer, Angelov, Lilyana, Barnett, Gene, Mohammadi, Alireza, Ahluwalia, Manmeet
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2020
Ämnen:
Clinical Trials: Immunologic
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651084/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.156
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk